Shiue‐Wei Lai

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Chi‐Tai Yeh · 3 shared papers, 2018–2022 · strength 0.36
   • Paper Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP1… DOI 10.1016/j.phymed.2022.154062↗
   • Paper Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancr… DOI 10.3390/cells9040911↗
   • Paper The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and … DOI 10.1007/s10585-018-9919-5↗
2. Tsu-Yi Chao · 2 shared papers, 2018–2020 · strength 0.22
   • Paper Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancr… DOI 10.3390/cells9040911↗
   • Paper The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and … DOI 10.1007/s10585-018-9919-5↗
3. Chung‐Ze Wu · 1 shared paper, 2022 · strength 0.15
   • Paper Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP1… DOI 10.1016/j.phymed.2022.154062↗
4. Jin‐Shuen Chen · 1 shared paper, 2022 · strength 0.15
   • Paper Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP1… DOI 10.1016/j.phymed.2022.154062↗
5. Alexander T.H. Wu · 1 shared paper, 2020 · strength 0.13
   • Paper Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancr… DOI 10.3390/cells9040911↗
6. Wen‐Chiuan Tsai · 1 shared paper, 2018 · strength 0.09
   • Paper The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and … DOI 10.1007/s10585-018-9919-5↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.